ARK Invest's position in KYMR, updated every trading day. Data as of 2026-11-12.
| Fund | Shares | Value | Weight | Rank |
|---|---|---|---|---|
| ARKG | 126,368 | $16.1M | 0.81% | #32 |
| Trade day | Fund | Side | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-11-03 | ARKG | Buy | Added | 8,211 | $1.0M |
| 2026-11-02 | ARKG | Buy | Added | 9,448 | $1.2M |
| 2026-10-13 | ARKG | Buy | Added | 3,669 | $391K |
| 2026-10-12 | ARKG | Buy | Added | 7,594 | $851K |
| 2026-10-09 | ARKG | Buy | Added | 2,344 | $263K |
| 2026-10-08 | ARKG | Buy | Added | 43,453 | $4.7M |
| 2026-10-07 | ARKG | Buy | Added | 24,895 | $2.7M |
| 2026-10-06 | ARKG | Buy | New position | 19,637 | $2.1M |
Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing KT-621, an oral STAT6 degrader in Phase 2b clinical trials for moderate to severe atopic dermatitis, asthma, COPD, EoE, CRSwNP, CSU, PN, BP,…
See KYMR's full ARK history since 2024, ARK's estimated cost basis, the conviction score and buy/sell alerts.
Open KYMR on FundWake →Data comes from ARK Invest's public daily holdings and trade files. FundWake is not affiliated with ARK Invest. Nothing here is investment advice.